Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.
Malcolm Frier
Index: Mini Rev. Med. Chem. 4(1) , 61-8, (2004)
Full Text: HTML
Abstract
The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.
Related Compounds
Related Articles:
Rhenium mixed-ligand complexes with S,N,S-tridentate thiosemicarbazone/thiosemicarbazide ligands.
2013-04-14
[Dalton Trans. 42(14) , 5111-21, (2013)]
2015-09-01
[J. Food Prot. 78 , 1719-28, (2015)]
2014-04-01
[Anticancer Res. 34(4) , 1679-89, (2014)]
2013-10-01
[Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 114 , 330-8, (2013)]
Natural selection on HFE in Asian populations contributes to enhanced non-heme iron absorption.
2015-01-01
[BMC Genet. 16 , 61, (2015)]